ZA201806325B - Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus - Google Patents

Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus

Info

Publication number
ZA201806325B
ZA201806325B ZA2018/06325A ZA201806325A ZA201806325B ZA 201806325 B ZA201806325 B ZA 201806325B ZA 2018/06325 A ZA2018/06325 A ZA 2018/06325A ZA 201806325 A ZA201806325 A ZA 201806325A ZA 201806325 B ZA201806325 B ZA 201806325B
Authority
ZA
South Africa
Prior art keywords
hepatitis
virus
pharmaceutical composition
nucleocapsid antigens
nucleocapsid
Prior art date
Application number
ZA2018/06325A
Other languages
English (en)
Inventor
Rubido Julio Cesar Aguilar
Mato Yadira Lobaina
Perez Enrique Iglesias
Arias Eduardo Penton
Nieto Gerardo Enrique Guillen
Santiago Jorge Agustin Aguiar
Blanco Sonia Gonzalez
Hernandez Jorge Valdes
Castillo Mariela Vazquez
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of ZA201806325B publication Critical patent/ZA201806325B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2018/06325A 2016-03-31 2018-09-20 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus ZA201806325B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CU2017/050001 WO2017167317A1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Publications (1)

Publication Number Publication Date
ZA201806325B true ZA201806325B (en) 2020-08-26

Family

ID=58671308

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/06325A ZA201806325B (en) 2016-03-31 2018-09-20 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus

Country Status (16)

Country Link
US (2) US11491218B2 (OSRAM)
EP (1) EP3437654B1 (OSRAM)
JP (1) JP6981992B2 (OSRAM)
KR (1) KR20180125985A (OSRAM)
CN (1) CN109219449B (OSRAM)
AR (1) AR108009A1 (OSRAM)
AU (1) AU2017243136B2 (OSRAM)
CU (1) CU24454B1 (OSRAM)
EA (1) EA201892212A1 (OSRAM)
ES (1) ES2965709T3 (OSRAM)
MX (1) MX2018011793A (OSRAM)
MY (1) MY202118A (OSRAM)
TW (1) TWI755383B (OSRAM)
UA (1) UA128952C2 (OSRAM)
WO (1) WO2017167317A1 (OSRAM)
ZA (1) ZA201806325B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4034158A4 (en) * 2019-09-23 2023-10-04 Ascendo Biotechnology, Inc. BIODEGRADABLE NANOCOMPLEX VACCINE, METHODS FOR SUPPRESSING HEPATITIS B VIRUS REPLICATION AND SECRETION OF HEPATITIS B VIRUS SURFACE ANTIGEN
EP4087858A1 (en) 2020-01-10 2022-11-16 Carogen Corporation Compositions and methods of use of oncolytic virus like vesicles
CU20200028A7 (es) 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia Nucleoproteína viral y formulaciones que la contienen
JP2025506732A (ja) * 2022-02-22 2025-03-13 カロジェン コーポレイション 感染症およびがんの免疫療法適用のための多用途のウイルス様小胞（ｖｌｖ）プラットフォーム
CN116218881B (zh) * 2022-10-21 2024-08-13 山东大学 一种治疗或者预防乙肝病毒的疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CN1164331C (zh) * 2001-05-23 2004-09-01 中国人民解放军第二军医大学 一种人乙型肝炎核酸疫苗
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN104338132A (zh) * 2013-07-26 2015-02-11 复旦大学 一种病毒免疫治疗药物复合物及其用途

Also Published As

Publication number Publication date
EA201892212A1 (ru) 2019-03-29
UA128952C2 (uk) 2024-12-11
BR112018069738A2 (pt) 2019-02-05
JP6981992B2 (ja) 2021-12-17
TW201735945A (zh) 2017-10-16
JP2019510064A (ja) 2019-04-11
HK1259329A1 (zh) 2019-11-29
EP3437654A1 (en) 2019-02-06
CU20160038A7 (es) 2017-11-07
ES2965709T3 (es) 2024-04-16
US11759517B2 (en) 2023-09-19
EP3437654B1 (en) 2023-09-20
MX2018011793A (es) 2018-12-17
MY202118A (en) 2024-04-04
US20200297840A1 (en) 2020-09-24
US20220193228A1 (en) 2022-06-23
KR20180125985A (ko) 2018-11-26
AU2017243136A1 (en) 2018-10-11
US11491218B2 (en) 2022-11-08
TWI755383B (zh) 2022-02-21
CN109219449A (zh) 2019-01-15
CN109219449B (zh) 2022-08-30
AR108009A1 (es) 2018-07-04
CA3017778A1 (en) 2017-10-05
CU24454B1 (es) 2019-11-04
WO2017167317A1 (es) 2017-10-05
AU2017243136B2 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
ZA201906252B (en) Hepatitis b virus surface antigen inhibitor
IL258326B (en) Antibodies that neutralize the hepatitis b virus in potency and their uses
SG10202007323VA (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
IL275427A (en) Hepatitis virus vaccines HBV) B) and their uses
ZA201807625B (en) Adeno-associated virus variant capsids and methods of use thereof
ZA202004538B (en) Influenza virus vaccines and uses thereof
IL275429A (en) Methods and device for administering hepatitis virus HBV vaccines) B)
IL249660B (en) Methods for treating hepatitis b virus and hepatitis d virus infections
IL277128A (en) Hepatitis B vaccines and their uses
PT3800257T (pt) Agentes pan-genotípicos contra o vírus influenza e métodos de utilização dos mesmos
GB201702193D0 (en) Hepatitis E virus vaccine
PL3407890T3 (pl) Preparat farmaceutyczny i jego zastosowanie w leczeniu wirusowego zapalenia krtani
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
HK40039938A (en) Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
HK40025470A (en) Nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus